The genetics and molecular biology of T-ALL.
Tiziana GirardiCarmen VicenteJan CoolsKim De KeersmaeckerPublished in: Blood (2017)
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy caused by the accumulation of genomic lesions that affect the development of T cells. For many years, it has been established that deregulated expression of transcription factors, impairment of the CDKN2A/2B cell-cycle regulators, and hyperactive NOTCH1 signaling play prominent roles in the pathogenesis of this leukemia. In the past decade, systematic screening of T-ALL genomes by high-resolution copy-number arrays and next-generation sequencing technologies has revealed that T-cell progenitors accumulate additional mutations affecting JAK/STAT signaling, protein translation, and epigenetic control, providing novel attractive targets for therapy. In this review, we provide an update on our knowledge of T-ALL pathogenesis, the opportunities for the introduction of targeted therapy, and the challenges that are still ahead.
Keyphrases
- copy number
- cell cycle
- acute lymphoblastic leukemia
- transcription factor
- mitochondrial dna
- dna methylation
- high resolution
- cell proliferation
- genome wide
- poor prognosis
- binding protein
- healthcare
- acute myeloid leukemia
- gene expression
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- mass spectrometry
- dna binding
- single molecule
- protein protein
- long non coding rna
- single cell
- stem cells
- mesenchymal stem cells
- cell therapy
- high speed
- tandem mass spectrometry